作者
Shinya Goto, Sylvia Haas, Walter Ageno, Samuel Z Goldhaber, Alexander GG Turpie, Jeffrey I Weitz, Pantep Angchaisuksiri, Joern Dalsgaard Nielsen, Gloria Kayani, Alfredo Farjat, Sebastian Schellong, Henri Bounameaux, Lorenzo G Mantovani, Paolo Prandoni, Ajay K Kakkar, GARFIELD-VTE Investigators
发表日期
2020/10/1
期刊
JAMA network open
卷号
3
期号
10
页码范围
e2022886-e2022886
出版商
American Medical Association
简介
Importance
Patients with venous thromboembolism (VTE) and concomitant chronic kidney disease (CKD) have been reported to have a higher risk of thrombosis and major bleeding complications compared with patients without concomitant CKD. The use of anticoagulation therapy is challenging, as many anticoagulant medications are excreted by the kidney. Large-scale data are needed to clarify the impact of CKD for anticoagulant treatment strategies and clinical outcomes of patients with VTE.
Objective
To compare clinical characteristics, treatment patterns, and 12-month outcomes among patients with VTE and concomitant moderate to severe CKD (stages 3-5) vs patients with VTE and mild to no CKD (stages 1-2) in a contemporary international registry.
Design, Setting, and Participants
The Global Anticoagulant Registry in the Field–Venous Thromboembolism (GARFIELD-VTE) study is a prospective …
学术搜索中的文章
S Goto, S Haas, W Ageno, SZ Goldhaber, AGG Turpie… - JAMA network open, 2020